Why Ascendis Pharma’s 182-week YORVIPATH data could matter for rare endocrine care
Find out how Ascendis Pharma’s YORVIPATH data could reshape hypoparathyroidism care and investor expectations.
Pharma & Biotech
Pharma & Biotech
Edgewise Therapeutics’ Phase 2 HCM data put systolic function into sharper focus
Find out how Edgewise Therapeutics’ EDG-7500 data could reshape HCM drug development as Phase 3 questions emerge.
Pharma & Biotech
Amani Therapeutics bets $25m on expanding clozapine access in schizophrenia
Amani Therapeutics raises $25M to advance AM-01, a fixed-dose clozapine combination targeting neutropenia. Analysis of what changes — and what risks remain.